MDT

86.04

-0.05%↓

120.64

-0.83%↓

VEEV

169.54

+0.98%↑

HQY

86.06

+0.15%↑

NEOG

9.56

+0.63%↑

MDT

86.04

-0.05%↓

120.64

-0.83%↓

VEEV

169.54

+0.98%↑

HQY

86.06

+0.15%↑

NEOG

9.56

+0.63%↑

MDT

86.04

-0.05%↓

120.64

-0.83%↓

VEEV

169.54

+0.98%↑

HQY

86.06

+0.15%↑

NEOG

9.56

+0.63%↑

MDT

86.04

-0.05%↓

120.64

-0.83%↓

VEEV

169.54

+0.98%↑

HQY

86.06

+0.15%↑

NEOG

9.56

+0.63%↑

MDT

86.04

-0.05%↓

120.64

-0.83%↓

VEEV

169.54

+0.98%↑

HQY

86.06

+0.15%↑

NEOG

9.56

+0.63%↑

Home・Aandelen Lijst・Pulmatrix Inc

Pulmatrix Inc

Open

1.29 6.61

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.21

Max

1.34

Belangrijke statistieken
By Trading Economics
Inkomsten	-51K -928K
EPS	-0.254
Werknemers	2
EBITDA	-51K -928K

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-7M 4.4M
Vorige openingsprijs	-5.32
Vorige sluitingsprijs	1.29

Pulmatrix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 apr 2026, 23:48 UTC

Belangrijke Nieuwsgebeurtenissen

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19 apr 2026, 23:36 UTC

Belangrijke Nieuwsgebeurtenissen

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19 apr 2026, 22:47 UTC

Belangrijke Nieuwsgebeurtenissen

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19 apr 2026, 21:14 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19 apr 2026, 21:14 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19 apr 2026, 23:49 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19 apr 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19 apr 2026, 23:38 UTC

Belangrijke Nieuwsgebeurtenissen

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19 apr 2026, 23:36 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19 apr 2026, 23:12 UTC

Belangrijke Nieuwsgebeurtenissen

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19 apr 2026, 23:10 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19 apr 2026, 23:09 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19 apr 2026, 23:08 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19 apr 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19 apr 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19 apr 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19 apr 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19 apr 2026, 20:03 UTC

Belangrijke Nieuwsgebeurtenissen

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19 apr 2026, 20:03 UTC

Belangrijke Nieuwsgebeurtenissen

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19 apr 2026, 20:03 UTC

Belangrijke Nieuwsgebeurtenissen

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19 apr 2026, 20:03 UTC

Belangrijke Nieuwsgebeurtenissen

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18 apr 2026, 01:00 UTC

Belangrijke Nieuwsgebeurtenissen

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 apr 2026, 22:58 UTC

Winsten

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 apr 2026, 21:32 UTC

Marktinformatie

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 apr 2026, 21:22 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 apr 2026, 21:22 UTC

Marktinformatie

Moody's Downgrades Belgium to A1 -- Market Talk

17 apr 2026, 20:52 UTC

Winsten

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

17 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 apr 2026, 20:29 UTC

Winsten

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Pulmatrix Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pulmatrix Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.